Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Net Income towards Common Stockholders fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year increase of 1491.11%. This contributed to the annual value of -$34.1 million for FY2024, which is 1916.98% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Net Income towards Common Stockholders stood at -$12.1 million, which was down 1659.63% from -$10.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Net Income towards Common Stockholders high stood at $1.4 million for Q1 2021, and its period low was -$22.9 million during Q4 2023.
  • For the 5-year period, SAB Biotherapeutics' Net Income towards Common Stockholders averaged around -$7.3 million, with its median value being -$7.1 million (2022).
  • As far as peak fluctuations go, SAB Biotherapeutics' Net Income towards Common Stockholders plummeted by 84592.72% in 2023, and later soared by 5014.74% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Net Income towards Common Stockholders stood at -$11.6 million in 2021, then surged by 31.83% to -$7.9 million in 2022, then plummeted by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then decreased by 5.9% to -$12.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$12.1 million for Q3 2025, versus -$10.1 million for Q2 2025 and -$5.2 million for Q1 2025.